Guardant Health announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share. Gross proceeds are approximately $90.7M, before deducting expenses payable by Guardant Health. Guardant Health intends to use the net proceeds from the offering primarily for general corporate purposes, including working capital, operating expenses and capital expenditures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GH:
- Guardant Health announces tentative date of FDA panel review of Shield test
- Guardant Health initiated with neutral view at Guggenheim, here’s why
- Guardant Health initiated with neutral view at Wolfe Research, here’s why
- Guardant Health initiated with neutral view at Wolfe Research
- Guardant Health, Cancer Research Horizons collaborate to advance cancer research
